Drug Profile
Amlodipine/candesartan cilexetil - Takeda
Alternative Names: Amlodipine besylate/candesartan cilexetil - Takeda; Candesartan cilexetil/amlodipine; TCV-116/amlodipine besilate; TCV-116CCB; UnisiaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Takeda
- Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 2 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 02 Aug 2019 No development reported - Preregistration for Hypertension in Taiwan, Thailand (PO)
- 08 Jun 2017 Takeda withdraws a phase III trial in Essential hypertension in China prior to enrolment due to business reasons (NCT02969265)
- 22 Dec 2016 Chemical structure information added